Our commitment to inflammation
At Galapagos, we believe we can have a meaningful impact on the lives of millions of people who currently live with an inflammatory disease and we are driven to make a difference.
Autoimmune and chronic inflammatory diseases (AICIDs) occur when the body’s immune system attacks its own cells and causes an inflammatory response.1,2 Chronic inflammatory diseases are currently estimated to affect one in every 20 people in Western society.3 Rheumatoid Arthritis (RA), Ulcerative Colitis (UC) are all examples of inflammatory conditions affecting around 5 million Europeans.4-6
These diseases bear a heavy cost on individuals that are living with the impact of the disease every day. For example, a person living with RA may struggle with simple everyday tasks such as tying their shoelaces or even combing their hair.7 Similarly, a person living with UC may severely limit their social life, relationships and their career out of fear of experiencing symptoms in a public place or with a partner.8
REFERENCES
1. Wang, L., Wang, F. S. & Gershwin, M. E. Human autoimmune diseases: a comprehensive update. J. Intern. Med. 278, 369–395 (2015) 2. Pahwa R, Goyal A, Bansal P, et al. Chronic Inflammation. [Updated 2020 Nov 20]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK493173/ 3. El-Gabalawy H, Guenther LC, Bernstein CN. Epidemiology of immune-mediated inflammatory diseases: incidence, prevalence, natural history, and comorbidities. J Rheumatol Suppl. 2010 May;85:2-10. doi: 10.3899/jrheum.091461 4. Burisch J, Jess T, Martinato M, Lakatos PL; ECCO -EpiCom. The burden of inflammatory bowel disease in Europe. J Crohns Colitis. 2013 May; 7(4):322-37 5. Galloway J, Capron JP, De Leonardis F, et al. The impact of disease severity and duration on cost, early retirement and ability to work in rheumatoid arthritis in Europe: an economic modelling study. Rheumatol Adv Pract. 2020;4(2):rkaa041. Published 2020 Sep 16. doi:10.1093/rap/rkaa041 6. Taylor PC, Moore A, Vasilescu R, Alvir J, Tarallo M. A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective. Rheumatology International. 2016;36(5):685-95 7. Armuzzi A and Liguori G. Quality of life in patients with moderate to severe ulcerative colitis and the impact of treatment: A narrative review. Digestive and Liver Disease. 2021;53:803-808. 8. Malm K, Bergman S, Andersson MLE, et al. Quality of life in patients with established rheumatoid arthritis: A phenomenographic study. SAGE Open Med. 2017;5:2050312117713647.
UK-IBD-NA-202203-00011 | Date of preparation December 2022
Adverse events should be reported.
For Great Britain, reporting forms and information can be found at yellowcard.mhra.gov.uk or via the Yellow Card app (download from the Apple App Store or Google Play Store).
Adverse events should also be reported to Galapagos via email to DrugSafety.UK.Ireland@glpg.com or 0800 072 7878.
Adverse events should be reported.
For Northern Ireland, reporting forms and information can be found at yellowcard.mhra.gov.uk or via the Yellow Card app (download from the Apple App Store or Google Play Store).
Adverse events should also be reported to Galapagos via email to DrugSafety.UK.Ireland@glpg.com or 0800 072 7878.
Adverse events should be reported.
For the Republic of Ireland, reporting forms and information can be found at www.hpra.ie and can be reported to HPRA on +353 1 6764971.
Adverse events should also be reported to Galapagos via email to DrugSafety.UK.Ireland@glpg.com or 00800 7878 1345.
Galapagos and the Galapagos logo are registered trademarks of Galapagos NV.
© 2022 Galapagos NV. All rights reserved.
GB-IBD-FIL-202208-00005 |
Date of preparation: October 2023
Contact Us
Galapagos Biotech Ltd
148 Belmont Rd, Uxbridge UB8 1QS
medicalinfo@glpg.com
Galapagos and the Galapagos logo are registered trademarks of Galapagos NV.
© 2022 Galapagos NV. All rights reserved.
GB-IBD-FIL-202208-00005 |
Date of preparation: October 2023
Contact Us
Galapagos Biotech Ltd
148 Belmont Rd, Uxbridge UB8 1QS
medicalinfo@glpg.com
© Copyright 2021 Galapagos NV
This link will take you away from the Galapagos website and you will be re-directed to a non-Galapagos website. Galapagos does not accept liability for sites controlled by third-parties.
*By choosing the "Healthcare Professional" option, you affirm your status as a healthcare professional in the UK and Ireland and acknowledge that you will receive promotional information pertaining to prescription-only medicines.
